GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

Sponsor
Imperial College London
Study ID
NCT06620185
Status
Recruiting
Apply to this trial

Conditions

  • Influenza

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • FLUENZ — BIOLOGICAL
    LAIV (Intranasal Influenza Vaccine)
  • Influenza challenge virus — BIOLOGICAL
    Influenza challenge virus (H3N2 strain)

Study Details

This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.

Key Dates

First listed
Oct 1, 2024
Start date
Apr 16, 2025
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LAIV
  • Experimental: IAV Challenge

Primary Outcome Measure

Peak symptoms related to inoculation with a GMP-adherent influenza A (H3N2) virus in healthy adults aged 18-55 [ Time Frame: 14 days ]

Central Contacts

Related Studies